Golden Drugs Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 17-11-2024
- Paid Up Capital ₹ 3.59 Cr
as on 17-11-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.00 Cr
as on 17-11-2024
- Satisfied Charges ₹ 24.50 Cr
as on 17-11-2024
- Revenue 48.64%
(FY 2023)
- Profit -23.53%
(FY 2023)
- Ebitda -137.17%
(FY 2023)
- Net Worth -72.98%
(FY 2023)
- Total Assets 25.31%
(FY 2023)
About Golden Drugs
The Corporate was formerly known as Golden Drug Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 3.59 Cr.
The company currently has active open charges totaling ₹20.00 Cr. The company has closed loans amounting to ₹24.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shailesh Siroya and Ravindrakumar Kothari serve as directors at the Company.
- CIN/LLPIN
U24232KA2012PTC157474
- Company No.
039907
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Aug 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- LocationBangalore, Karnataka
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Golden Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Siroya  | Director | 12-Apr-2018 | Current |
| Ravindrakumar Kothari | Director | 15-Nov-2018 | Current |
Financial Performance of Golden Drugs.
Golden Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.64% increase. The company also saw a substantial fall in profitability, with a 23.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 72.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Golden Drugs?
In 2023, Golden Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Lifezen Healthcare Private LimitedActive 10 years 1 month
Shailesh Siroya and Ravindrakumar Kothari are mutual person
Balance Clinics LlpActive 10 years 7 monthsShailesh Siroya and Ravindrakumar Kothari are mutual person
- Aurum Research & Analytical Solutions Private LimitedActive 1 year 4 months
Shailesh Siroya is a mutual person
- Bal Research FoundationActive 10 years 1 month
Shailesh Siroya and Ravindrakumar Kothari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Feb 2024 | ₹20.00 Cr | Open |
Tata Capital Financial Services Limited Creation Date: 28 Sep 2018 | ₹15.00 Cr | Satisfied |
Punjab National Bank Creation Date: 15 Oct 2014 | ₹5.50 Cr | Satisfied |
How Many Employees Work at Golden Drugs?
Golden Drugs has a workforce of 68 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Golden Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golden Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
